Baseline table of total population and PS matched sample
| Original sample | Matched sample | Missing | |||||
| Overall | Patients without a CT-first strategy | CT-first | Overall | Patients without a CT-first strategy | CT-first | % | |
| n | 33 068 | 30 756 | 2312 | 12 545 | 10 237 | 2308 | |
| Age (mean (SD))*† | 56 (13.41) | 55 (13.63) | 57 (9.85) | 57 (12.62) | 57 (13.16) | 57 (9.85) | 0.0 |
| Female (%)*† | 17 622 (53.3) | 16 329 (53.1) | 1293 (55.9) | 7068 (56.3) | 5779 (56.5) | 1289 (55.8) | 0.0 |
| Hypertension (%)*† | 9668 (29.4) | 8966 (29.3) | 702 (30.4) | 3920 (31.2) | 3220 (31.5) | 700 (30.3) | 0.5 |
| Dyslipidaemia (%)*† | 5475 (16.6) | 5084 (16.6) | 391 (16.9) | 2127 (17.0) | 1737 (17.0) | 390 (16.9) | 0.5 |
| Diabetes (%)*† | 2734 (8.3) | 2559 (8.4) | 175 (7.6) | 978 (7.8) | 803 (7.8) | 175 (7.6) | 0.6 |
| Height (mean (SD))*† | 173 (9.99) | 173 (9.99) | 173 (9.96) | 172.52 (9.92) | 172.50 (9.91) | 172.61 (9.96) | 1.1 |
| Weight (mean (SD))*† | 80 (16.13) | 80 (16.15) | 80 (15.86) | 80.02 (16.30) | 80.04 (16.40) | 79.95 (15.86) | 1.1 |
| BMI (mean (SD))*† | 27 (4.71) | 27 (4.72) | 27 (4.60) | 27 (4.75) | 27 (4.78) | 27 (4.61) | 1.2 |
| Chest pain category (%)*† | 56.4 | ||||||
| Non-anginal | 8198 (56.8) | 7723 (58.5) | 475 (39.0) | 1965 (36.7) | 1490 (36.1) | 475 (39.1) | |
| Atypical | 2092 (14.5) | 1906 (14.4) | 186 (15.3) | 861 (16.1) | 675 (16.3) | 186 (15.3) | |
| Typical | 4131 (28.6) | 3574 (27.1) | 557 (45.7) | 2521 (47.1) | 1967 (47.6) | 554 (45.6) | |
| Smoking status (%)*† | 6.3 | ||||||
| Current | 13 050 (42.1) | 12 285 (42.6) | 765 (35.5) | 4067 (35.0) | 3303 (34.9) | 764 (35.5) | |
| Former | 9907 (32.0) | 9156 (31.7) | 751 (34.9) | 4091 (35.2) | 3342 (35.3) | 749 (34.8) | |
| Never | 8041 (25.9) | 7404 (25.7) | 637 (29.6) | 3456 (29.8) | 2819 (29.8) | 637 (29.6) | |
| Family history of atherosclerosis (%)*† | 11 644 (35.2) | 10 593 (34.4) | 1051 (45.5) | 5662 (45.1) | 4615 (45.1) | 1047 (45.4) | 0.0 |
| Consult year (%)*† | 0.0 | ||||||
| 2007–2010 | 4344 (13.1) | 4319 (14.0) | 25 (1.1) | 133 (1.1) | 108 (1.1) | 25 (1.1) | |
| 2011–2014 | 14 362 (43.4) | 13 234 (43.0) | 1128 (48.8) | 6025 (48.0) | 4900 (47.9) | 1125 (48.7) | |
| 2015–2018 | 14 362 (43.4) | 13 203 (42.9) | 1159 (50.1) | 6387 (50.9) | 5229 (51.1) | 1158 (50.2) | |
| Diagnosis of CHD at baseline (%)*† | 2731 (8.3) | 2612 (8.5) | 119 (5.1) | 659 (5.3) | 540 (5.3) | 119 (5.2) | 0.0 |
| Diagnosis of cerebrovascular disease at baseline (%)*† | 975 (2.9) | 918 (3.0) | 57 (2.5) | 303 (2.4) | 246 (2.4) | 57 (2.5) | 0.0 |
| Medication prescribed at baseline, n (%) | |||||||
| Aspirin*† | 1209 (3.7) | 1130 (3.7) | 79 (3.4) | 442 (3.5) | 363 (3.5) | 79 (3.4) | 0.0 |
| Betablocker*† | 1266 (3.8) | 1171 (3.8) | 95 (4.1) | 537 (4.3) | 442 (4.3) | 95 (4.1) | 0.0 |
| Calcium channel blocker*† | 608 (1.8) | 572 (1.9) | 36 (1.6) | 184 (1.5) | 148 (1.4) | 36 (1.6) | 0.0 |
| Nitrate*† | 522 (1.6) | 498 (1.6) | 24 (1.0) | 124 (1.0) | 100 (1.0) | 24 (1.0) | 0.0 |
| Statin*† | 1335 (4.0) | 1259 (4.1) | 76 (3.3) | 415 (3.3) | 339 (3.3) | 76 (3.3) | 0.0 |
| Conclusion of exercise test (%)*† | 17.7 | ||||||
| Abnormal | 2295 (8.4) | 1949 (7.7) | 346 (18.7) | 1570 (15.6) | 1227 (15.0) | 343 (18.6) | |
| Inconclusive | 5622 (20.7) | 5113 (20.2) | 509 (27.5) | 2960 (29.5) | 2452 (29.9) | 508 (27.5) | |
| Normal | 19 308 (70.9) | 18 311 (72.2) | 997 (53.8) | 5518 (54.9) | 4521 (55.1) | 997 (54.0) | |
| Domestic region in the NL (%)*† | 0.0 | ||||||
| Middle | 13 991 (42.3) | 12 693 (41.3) | 1298 (56.1) | 7103 (56.6) | 5809 (56.7) | 1294 (56.1) | |
| North | 17 339 (52.4) | 16 344 (53.1) | 995 (43.0) | 5332 (42.5) | 4337 (42.4) | 995 (43.1) | |
| South | 1738 (5.3) | 1719 (5.6) | 19 (0.8) | 110 (0.9) | 91 (0.9) | 19 (0.8) | |
| Total cholesterol in mmol/L (mean (SD))*† | 5.15 (1.13) | 5.13 (1.13) | 5.33 (1.17) | 5.32 (1.16) | 5.31 (1.16) | 5.33 (1.16) | 24.4 |
| 10-year HeartSCORE in % (median (IQR)) | 1.75(0.47, 4.97) | 1.73(0.44, 5.03) | 1.92(0.75, 4.46) | 2.04(0.60, 5.45) | 2.08(0.57, 5.67) | 1.91(0.75, 4.47) | 30.9 |
| Pretest probability (median (IQR)) | 10 (3–22) | 10 (3–22) | 13 (6–22) | 13.00 (6.00–26.00) | 13.00 (6.00–32.00) | 13.00 (6.00–22.00) | 61.8 |
| Pretest probability of CAD in %, n (%) | 61.8 | ||||||
| High >15% | 4412 (34.9) | 3939 (34.2) | 473 (41.7) | 2128 (45.0) | 1657 (46.0) | 471 (41.6) | |
| Intermediate 5%–15% | 4028 (31.9) | 3600 (31.3) | 428 (37.7) | 1512 (31.9) | 1085 (30.1) | 427 (37.8) | |
| Low <%5 | 4199 (33.2) | 3966 (34.5) | 233 (20.5) | 1093 (23.1) | 860 (23.9) | 233 (20.6) | |
| All-cause mortality (%)* | 1331 (4.0) | 1288 (4.2) | 43 (1.9) | 406 (3.2) | 363 (3.5) | 43 (1.9) | 0.0 |
| Cardiovascular mortality (%) | 329 (1.0) | 313 (1.0) | 16 (0.7) | 111 (0.9) | 95 (0.9) | 16 (0.7) | 0.0 |
| Follow-up in years (median (IQR)) | 5.5 (3.4–7.8) | 5.6 (3.4–7.9) | 5.1 (3.3–6.9) | 4.9 (3.2–6.7) | 4.9 (3.2–6.7) | 5.1 (3.3–6.8) | 0.0 |
| Nelson-Aalen estimator* (median (IQR)) | 0.0348 (0.0189–0.0579) | 0.0354 (0.0188–00594) | 0.0313 (0.0187–0.0472) | 0.0302 (0.0181–0.0463) | 0.0301 (0.0179–0.0460) | 0.0312 (0.0187–0.0472) | |
Baseline table representing the distribution of baseline variables before and after matching on the PS. Pretest probability is derived from the 2019, ESC Guidelines.12 24 The summary statistics are shown as the data before imputation. Missing are the percentage of missing observations in the total population.
*Variables used for multiple imputation.
†Variables used for calculation of PS.
BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; ESC, European Society of Cardiology; PS, propensity score.